Chemotherapeutic neuropathy
- 1 October 1999
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Neurology
- Vol. 12 (5), 565-571
- https://doi.org/10.1097/00019052-199910000-00010
Abstract
Peripheral neurotoxicity is a dose-limiting side-effect for a number of effective chemotherapeutic agents, including platinum compounds, taxanes, and vinca alkaloids. New experimental chemotherapy drugs that cause neuropathy include suramin and Dolostatin-10. A better understanding of cellular mechanisms will lead to novel treatment strategies that will protect neurons without decreasing therapeutic efficacy.Keywords
This publication has 58 references indexed in Scilit:
- Oxaliplatin: A review of preclinical and clinical studiesAnnals of Oncology, 1998
- Carboplatin toxic effects on the peripheral nervous system of the ratAnnals of Oncology, 1998
- Oxaliplatin in practiceBritish Journal of Cancer, 1998
- Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatinBritish Journal of Cancer, 1997
- Evaluation of neuropathy in patients on suramin treatmentMuscle & Nerve, 1997
- A prospective study of suramin-induced peripheral neuropathyBrain, 1996
- Peripheral neuropathy secondary to docetaxel (Taxotere)Neurology, 1996
- Peripheral neurotoxicity induced by docetaxelNeurology, 1996
- Comparative Adverse Effect Profiles of Platinum DrugsDrug Safety, 1995
- Suramin‐induced polyneuropathyNeurology, 1990